Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer

NCT05555706 is registered in ClinicalTrials.gov with Shanghai Jiaolian Drug Research and Development Co., Ltd as lead sponsor.

NCT NCT05555706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study to Evaluate the Efficacy and Safety of B013 in Combination With Nab-Paclitaxel in First-line Treatment for Patients With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase
Phase 2/3
Overall status
Completed
Start date
December 6, 2022
Completion date
September 30, 2024
Enrollment
62 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc)